Vimeo
LinkedIn
Instagram
Share |

pharmaceutical

April 25, 2019

How is one Chinese biotechnology group succeeding in supporting the earliest stage of new drug discovery when global pharmaceutical companies have given up? Dr Jun Mao, founder and chairwoman of Viva Ventures, explains how it leverages its in-house expertise to invest in hundreds of biotech startups in the $20 trillion global pharmaceutical and biotechnology market. 

Viva Ventures has a long history in supporting drug discovery for disease cures in China and the United States, can you explain more about the market opportunity?

January 25, 2012

Relinquishing control can often be difficult for company founders, but one Indian family business head is currently in the process of ensuring succession at his firm goes well.

Relinquishing control can often be difficult for company founders, but one Indian family business head is currently in the process of ensuring succession at his firm goes well.

July 1, 2007

With a production cycle lasting a decade and large conglomerates threatening to swoop, it can be difficult for family-owned pharmaceutical companies to remain both profitable and independent. Andrea Chipman talks to a select few who have made it – Roche, Boehringer, Servier and Stiefel – to learn their strategies for success

Andrea Chipman is a freelance journalist based in the UK.

With a production cycle lasting a decade and large conglomerates threatening to swoop, it can be difficult for family-owned pharmaceutical companies to remain both profitable and independent. Andrea Chipman talks to a select few who have made it – Roche, Boehringer, Servier and Stiefel – to learn their strategies for success

In 2006, the pharmaceutical sector saw another round of consolidation as industry giants gobbled up medium-sized players that had struggled to remain on their own.

Click here >>
Close